Our findings indicate that the breast cancers most likely to be sensitive to Akt inhibitors would be those displaying high Akt, low SGK1 mRNA/protein and in which phosphorylation of NDRG1 is suppressed by Akt inhibitors. The gene discussed is NDRG1; the disease is breast cancer.